Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

被引:177
作者
Brenner, BG
Routy, JP
Petrella, M
Moisi, D
Oliveira, M
Detorio, M
Spira, B
Essabag, V
Conway, B
Lalonde, R
Sekaly, RP
Wainberg, MA
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, AIDS Ctr, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Ctr Hlth, Montreal, PQ H3T 1E2, Canada
[3] Univ Montreal, Montreal, PQ, Canada
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1128/JVI.76.4.1753-1761.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This study examines the persistence and fitness of multidrug-resistant (MDR) viruses acquired during primary human immunodeficiency virus infection (PHI). In four individuals, MDR infections persisted over the entire study period, ranging from 36 weeks to 5 years, in the absence of antiretroviral therapy. In stark contrast, identified source partners in two cases showed expected outgrowth of wild-type (WT) virus within 12 weeks of treatment interruption. In the first PHI case, triple-class MDR resulted in low plasma viremia (1.6 to 3 log copies/ml) over time compared with mean values obtained for an untreated PHI group harboring WT infections (4.1 to 4.3 log copies/ml). Increasing viremia in PHI patient 1 at week 52 was associated with the de novo emergence of a protease inhibitor-resistant variant through a recombination event involving the original MDR virus. MDR infections in two other untreated PHI patients yielded viremia levels typical of the untreated WT group. A fourth patient's MDR infection yielded low viremia (<50 to 500 copies/ml) for 5 years despite his having phenotypic resistance to all antiretroviral drugs in his treatment regimen. In two of these PHI cases, a rebound to higher levels of plasma viremia only occurred when the M184V mutation in reverse transcriptase could no longer be detected and, in a third case, nondetection of M184V was associated with an inability to isolate virus. To further evaluate the fitness of MDR variants acquired in PHI, MDR and corresponding WT viruses were isolated from index and source partners, respectively. Although MDR viral infectivity (50% tissue culture infective dose) was comparable to that observed for WT viruses, MDR infections in each case demonstrated 2-fold and 13- to 23-fold reductions in p24 antigen and reverse transcriptase enzymatic activity, respectively. In dual-infection competition assays, MDR viruses consistently demonstrated a marked replicative disadvantage compared with WT virus. These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence.
引用
收藏
页码:1753 / 1761
页数:9
相关论文
共 34 条
  • [21] Selective vertical transmission of HIV: lamivudine-resistant maternal clone undetectable by conventional resistance testing
    Niehues, T
    Walter, H
    Homeff, G
    Wahn, V
    Schmidt, B
    [J]. AIDS, 1999, 13 (17) : 2482 - 2484
  • [22] Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
    Nijhuis, M
    Schuurman, R
    de Jong, D
    Erickson, J
    Gustchina, E
    Albert, J
    Schipper, P
    Gulnik, S
    Boucher, CAB
    [J]. AIDS, 1999, 13 (17) : 2349 - 2359
  • [23] A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
    Quiñones-Mateu, ME
    Ball, SC
    Marozsan, AJ
    Torre, VS
    Albright, JL
    Vanham, G
    van der Groën, G
    Colebunders, RL
    Arts, EJ
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (19) : 9222 - 9233
  • [24] Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
    Salomon, H
    Wainberg, MA
    Brenner, B
    Quan, YD
    Rouleau, D
    Coté, P
    LeBlanc, R
    Lefebvre, E
    Spira, B
    Tsoukas, C
    Sekaly, RP
    Conway, B
    Mayers, D
    Routy, JP
    [J]. AIDS, 2000, 14 (02) : F17 - F23
  • [25] COMPARISON OF CORD-BLOOD AND PERIPHERAL-BLOOD MONONUCLEAR-CELLS AS TARGETS FOR VIRAL ISOLATION AND DRUG-SENSITIVITY STUDIES INVOLVING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    SALOMON, H
    BELMONTE, A
    NGUYEN, K
    GU, ZX
    GELFAND, M
    WAINBERG, MA
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (08) : 2000 - 2002
  • [26] Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy
    Servais, J
    Lambert, C
    Fontaine, E
    Plesséria, JM
    Robert, I
    Arendt, V
    Staub, T
    Schneider, F
    Hemmer, R
    Burtonboy, G
    Schmit, JC
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (02) : 454 - 459
  • [27] Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
    Sharma, PL
    Crumpacker, CS
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (11) : 8846 - 8851
  • [28] LONG-TERM PERSISTENCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN PLASMA ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 OF DIDEOXYINOSINE-TREATED PATIENTS REMOVED FROM ZIDOVUDINE THERAPY
    SMITH, MS
    KOERBER, KL
    PAGANO, JS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (01) : 184 - 188
  • [29] Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
    Stuyver, L
    Wyseur, A
    Rombout, A
    Louwagie, J
    Scarcez, T
    Verhofstede, C
    Rimland, D
    Schinazi, RF
    Rossau, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) : 284 - 291
  • [30] Van Vaerenbergh K, 2000, AIDS RES HUM RETROV, V16, P529